Acquisitions - Narrative (Details) (USD $)	12 Months Ended			0 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended	1 Months Ended		12 Months Ended	0 Months Ended	1 Months Ended	12 Months Ended					0 Months Ended	1 Months Ended			25 Months Ended				12 Months Ended					1 Months Ended				12 Months Ended					12 Months Ended	3 Months Ended				12 Months Ended							12 Months Ended				0 Months Ended			1 Months Ended				0 Months Ended	1 Months Ended				12 Months Ended				12 Months Ended		0 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 19, 2012 Thomas Medical Products, Inc [Member]	Dec. 31, 2012 Thomas Medical Products, Inc [Member]	Nov. 19, 2012 MediGroup [Member]	Dec. 31, 2012 MediGroup [Member]	Jan. 31, 2012 Ostial Solutions, LLC [Member]	Aug. 31, 2012 Ostial Solutions, LLC [Member]	Jan. 31, 2012 Ostial Solutions, LLC [Member]	Dec. 31, 2012 Ostial Solutions, LLC [Member]	Sep. 02, 2011 Ash [Member]	Sep. 30, 2011 Ash [Member]	Dec. 31, 2012 Ash [Member]	Dec. 31, 2012 BioSphere [Member]	Dec. 31, 2011 BioSphere [Member]	Dec. 31, 2010 BioSphere [Member]	Sep. 10, 2010 BioSphere [Member]	Feb. 19, 2010 Developed technology [Member]	Apr. 30, 2011 Developed technology [Member]	Nov. 30, 2010 Developed technology [Member]	May 31, 2010 Developed technology [Member]	Feb. 28, 2012 Developed technology [Member]	Dec. 31, 2012 Developed technology [Member]	Dec. 31, 2011 Developed technology [Member]	Apr. 06, 2011 Developed technology [Member]	Dec. 31, 2012 Developed technology [Member] Thomas Medical Products, Inc [Member]	Dec. 31, 2012 Developed technology [Member] MediGroup [Member]	Dec. 31, 2012 Developed technology [Member] Ostial Solutions, LLC [Member]	Dec. 31, 2012 Developed technology [Member] Ash [Member]	Dec. 31, 2011 Developed technology [Member] BioSphere [Member]	Aug. 31, 2011 Developed Technology Rights, Acquired in August 2011, Two [Member]	Aug. 31, 2011 Developed Technology Rights, Acquired in August 2011, One [Member]	Dec. 31, 2012 Non-compete agreements [Member]	Dec. 31, 2011 Non-compete agreements [Member]	Dec. 31, 2012 Non-compete agreements [Member] Thomas Medical Products, Inc [Member]	Dec. 31, 2012 Non-compete agreements [Member] MediGroup [Member]	Dec. 31, 2012 Non-compete agreements [Member] Ostial Solutions, LLC [Member]	Dec. 31, 2012 License agreements and trademarks [Member]	Dec. 31, 2011 License agreements and trademarks [Member]	Dec. 31, 2011 License agreements and trademarks [Member] BioSphere [Member]	Dec. 31, 2010 Customer Lists [Member]	Dec. 31, 2012 Customer Lists [Member]	Jan. 05, 2012 Customer Lists [Member]	Dec. 31, 2011 Customer Lists [Member]	Dec. 31, 2012 Customer Lists [Member] Thomas Medical Products, Inc [Member]	Dec. 31, 2012 Customer Lists [Member] MediGroup [Member]	Dec. 31, 2012 Customer Lists [Member] Ostial Solutions, LLC [Member]	Dec. 31, 2012 Customer Lists [Member] Ash [Member]	Dec. 31, 2011 Customer Lists [Member] BioSphere [Member]	Dec. 31, 2012 Trademarks [Member]	Dec. 31, 2011 Trademarks [Member]	Dec. 31, 2012 Trademarks [Member] Thomas Medical Products, Inc [Member]	Dec. 31, 2012 Trademarks [Member] MediGroup [Member]	Dec. 31, 2012 Trademarks [Member] Ostial Solutions, LLC [Member]	Dec. 31, 2011 Trademarks [Member] BioSphere [Member]	Aug. 27, 2012 License Agreement Terms [Member]	Aug. 21, 2012 Distribution agreements [Member]	Jan. 05, 2012 Distribution agreements [Member]	May 31, 2012 Distribution agreements [Member]	Jan. 31, 2012 Distribution agreements [Member]	Dec. 31, 2012 Distribution agreements [Member]	Dec. 31, 2011 Distribution agreements [Member]	Aug. 07, 2012 Blockade Medical LLC [Member]	May 31, 2012 Intellectual Property Rights [Member]	Dec. 31, 2011 Intellectual Property Rights [Member]	Jul. 31, 2011 Intellectual Property Rights [Member]	Jun. 30, 2011 Intellectual Property Rights [Member]	Dec. 31, 2011 Intellectual Property Rights [Member]	Dec. 31, 2012 Intellectual Property Rights [Member]	Dec. 15, 2011 Intellectual Property Rights [Member]	Jul. 18, 2011 Intellectual Property Rights [Member]	Dec. 31, 2011 Development of Biomaterial Technology [Member]	Dec. 31, 2011 Covered Biliary In-Process Research and Development [Member]	Dec. 19, 2012 Wells Fargo Credit Agreement [Member]	Sep. 10, 2010 Wells Fargo Credit Agreement [Member] BioSphere [Member]	Aug. 07, 2012 Special Membership Units [Member] Blockade Medical LLC [Member]
Business Acquisition [Line Items]
Payments to acquire businesses				$ 167,000,000		$ 4,000,000			$ 6,500,000	$ 10,000,000			$ 5,000,000
Contingent consideration, potential payment								13,500,000				1,000,000																																														250,000
Liabilities incurred				445,000
Net sales					1,900,000		169,000				457,000						9,000,000
Income before tax					51,000
Acquired receivables					6,500,000													4,600,000
Estimated uncollectible trade receivables acquired					34,000													51,000
Useful life																			10 years								8 years	8 years	15 years	15 years	15 years					3 years	7 years	5 years			10 years	10 years				12 years	8 years	8 years	2 years	10 years			15 years	15 years	15 years	15 years	3 years	10 years	12 years
Weighted average useful life					8 years 6 months 18 days		8 years 1 month 24 days				14 years 7 months 6 days			9 years		13 years 7 months 6 days
Long-term debt issuance costs	3,706,000	0	522,000																																																																								3,700,000	522,000
Contingent consideration, payment, 2013						150,000
Contingent consideration, payment, 2014						150,000
Contingent consideration, payment, 2015						150,000
Contingent consideration, potential payment, 2016						150,000
Contingent consideration, potential payment, 2017						150,000
Contingent consideration, potential payment, 2018						150,000
Contingent consideration, potential payment, 2019						150,000
Contingent consideration, potential payment, 2020						150,000
Contingent consideration, potential payment, 2021						150,000
Contingent consideration, potential payment, 2022						150,000
Potential payment, annual increase in net sales, minimum percent						8.00%
Contingent consideration, liability						403,000		4,300,000		4,300,000		1,300,000
Consideration transferred																		95,700,000
Payments to acquire intangible assets	1,460,000	2,077,000	1,083,000																	500,000	250,000	250,000	250,000									500,000	250,000																								750,000	250,000		1,000,000	1,500,000
Intangible assets purchased																			1,000,000					87,332,000	35,415,000	1,000,000								875,000	207,000				1,872,000	1,547,000		1,300,000	12,430,000	95,000	8,491,000						5,949,000	4,732,000					750,000	250,000	2,500,000			3,875,000	1,526,000
Acquired in-process research and development	2,450,000	5,838,000	0																																																														1,000,000	2,000,000	1,000,000	1,000,000	4,900,000				500,000	400,000
Research and development, contingent consideration, liability																																																																				3,500,000			1,000,000	1,000,000
Research and development, contingent consideration, discounted liability																																																																		948,000			948,000	968,000
Payments to Acquire Investments																																																																1,000,000
Cost method investments, special membership units																																																																													422,594
Cost method investments, ownership percentage																																																																11.90%
Adjustment related to previous acquisitions	280,000	(228,000)												280,000	(228,000)
Acquisition-related costs					$ 2,700,000										$ 86,000	$ 2,500,000